Searchable database of clinical trials and peer-reviewed studies on medical cannabis.
Showing 30 of 30 studies
Key Findings: CBD (600mg) significantly reduced anxiety, cognitive impairment, and discomfort during public speaking test compared to placebo.
View Full StudyKey Findings: Median seizure frequency decreased by 36.5%. 2% of patients became seizure-free. FDA approval for Epidiolex followed.
View Full StudyKey Findings: Moderate-quality evidence supports cannabinoids for chronic pain. 30% reduction in pain scores vs placebo.
View Full StudyKey Findings: Nabiximols (Sativex) significantly improved spasticity scores. 74% of patients achieved ≥20% improvement.
View Full StudyKey Findings: Cannabis users showed greater PTSD symptom reduction over 8 weeks. CBD-dominant products most effective.
View Full StudyKey Findings: Dronabinol significantly reduced delayed CINV. 71% complete response vs 22% placebo.
View Full StudyKey Findings: Short-term cannabis use may improve sleep latency and duration. Long-term use associated with tolerance and withdrawal insomnia.
View Full StudyKey Findings: Transdermal CBD reduced joint swelling and pain behaviors in arthritic rats. Dose-dependent effects observed.
View Full StudyKey Findings: THC reduces IOP for 3-4 hours. Frequent dosing required. CBD may increase IOP. Not recommended as primary treatment.
View Full StudyKey Findings: Cannabis improved quality of life and reduced disease activity in Crohn's patients. 45% achieved remission vs 10% placebo.
View Full StudyKey Findings: 79.2% of patients showed decreased anxiety scores within first month. 66.7% reported improved sleep. Minimal side effects reported.
View Full StudyKey Findings: Average pain reduction of 3.0 points on 0-10 scale. 44% reduced or eliminated opioid use. Quality of life improved significantly.
View Full StudyKey Findings: Sleep quality improved in 66.7% of patients. Anxiety decreased in 79.2%. Average dose: 25-175mg CBD daily.
View Full StudyKey Findings: Significant CAPS-5 score reduction in all cannabis groups vs placebo. THC-dominant showed greatest improvement in hyperarousal symptoms.
View Full StudyKey Findings: Moderate evidence for pain reduction in advanced cancer. Nabiximols showed 30% pain reduction vs placebo. NNT of 6.
View Full StudyKey Findings: CBD (600mg) significantly reduced anxiety, cognitive impairment, and altered brain activity in limbic and paralimbic areas.
View Full StudyKey Findings: Moderate-quality evidence for neuropathic pain reduction. 30% achieved ≥30% pain relief. NNT of 6 for significant benefit.
View Full StudyKey Findings: CBD (75-300mg) improved REM sleep behavior disorder symptoms. Reduced nightmares and improved sleep quality without side effects.
View Full StudyKey Findings: Preclinical evidence strongly supports CBD for GAD, panic disorder, SAD, OCD, and PTSD. Human studies show acute anxiolytic effects.
View Full StudyKey Findings: After 6 months, 50% stopped other pain medications. Significant improvement in pain scores and quality of life. Well-tolerated.
View Full StudyKey Findings: Nabiximols as effective as ondansetron for delayed CINV. 71% complete response. Better appetite stimulation than standard antiemetics.
View Full StudyKey Findings: 91% reduction in PTSD nightmare frequency. Average dose 12-25mg CBD at bedtime. No adverse effects reported.
View Full StudyKey Findings: After 6 months: 44% reported pain reduction >30%. 18% stopped opioids. Quality of life improved in 70% of patients.
View Full StudyKey Findings: Significant improvement in sleep disturbance scores. Pain intensity reduced by 2.7 points on 0-10 scale. Spasticity improved.
View Full StudyKey Findings: CBD pretreatment significantly reduced anxiety, cognitive impairment, and discomfort during public speaking. Comparable to ipsapirone.
View Full StudyKey Findings: Strong evidence for CINV, pain, and appetite stimulation. Emerging evidence for anti-tumor effects. Well-tolerated in cancer patients.
View Full StudyKey Findings: 94% reported improved quality of life. 53% reduced opioid use. Average pain reduction of 3.5 points. Minimal adverse effects.
View Full StudyKey Findings: High-dose CBD (160mg) increased total sleep time and reduced sleep latency. No hangover effect. Well-tolerated.
View Full StudyKey Findings: 75% reduction in CAPS scores. Improved sleep quality and reduced nightmares. 60% reduced or stopped psychiatric medications.
View Full StudyKey Findings: Significant pain reduction in opioid-refractory cancer patients. 30% achieved ≥30% pain relief. Improved sleep and quality of life.
View Full Study